kr20.85
4.14% day before yesterday
Stockholm, Jan 05, 01:00 pm CET
ISIN
SE0002485979
Symbol
GENO

Genovis Stock price

kr20.85
+0.50 2.46% 1M
-8.65 29.32% 6M
-0.40 1.88% YTD
-2.80 11.84% 1Y
-22.80 52.23% 3Y
-14.45 40.93% 5Y
+18.75 892.86% 10Y
-86.15 80.51% 20Y
Stockholm, Closing price Mon, Jan 05 2026
-0.90 4.14%

Key metrics

Basic
Market capitalization
kr1.4b
Enterprise Value
kr1.4b
Net debt
positive
Cash
kr154.9m
Shares outstanding
66.1m
Valuation (TTM | estimate)
P/E
65.2 | 60.1
P/S
12.3 | 11.1
EV/Sales
11.6 | 10.5
EV/FCF
39.0
P/B
5.5
Financial Health
Equity Ratio
69.6%
Return on Equity
14.4%
ROCE
5.3%
ROIC
-
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
kr116.6m | kr129.0m
EBITDA
kr29.6m | kr34.7m
EBIT
kr18.6m | kr21.9m
Net Income
kr21.2m | kr22.9m
Free Cash Flow
kr34.7m
Growth (TTM | estimate)
Revenue
-10.1% | -1.0%
EBITDA
-43.1% | -13.1%
EBIT
-54.5% | -25.5%
Net Income
-24.1% | -30.4%
Free Cash Flow
22.3%
Margin (TTM | estimate)
Gross
90.3%
EBITDA
25.4% | 26.9%
EBIT
15.9%
Net
18.2% | 17.8%
Free Cash Flow
29.8%
More
EPS
kr0.3
FCF per Share
kr0.5
Short interest
-
Employees
32
Rev per Employee
kr4.1m
Show more

Is Genovis a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,084 stocks worldwide.

Genovis Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Genovis forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Genovis forecast:

Buy
88%
Hold
13%

Financial data from Genovis

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
117 117
10% 10%
100%
- Direct Costs 11 11
75% 75%
10%
105 105
25% 25%
90%
- Selling and Administrative Expenses 44 44
3% 3%
37%
- Research and Development Expense - -
-
-
30 30
43% 43%
25%
- Depreciation and Amortization 11 11
2% 2%
9%
EBIT (Operating Income) EBIT 19 19
54% 54%
16%
Net Profit 21 21
24% 24%
18%

In millions SEK.

Don't miss a Thing! We will send you all news about Genovis directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Genovis AB engages in the research and development of enzyme products. Its product portfolio includes SmartEnzymes, which offers to pharmaceutical and medical device industries tools that facilitate the development of new treatment methods and diagnostics. The company was founded by Inga Sarah Maria Fredriksson in 1999 and is headquartered in Lund, Sweden.

Head office Sweden
CEO Mr. Olsson
Employees 32
Founded 1999
Website www.genovis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today